ARGENX SE-ADR (ARGX) Rating Increased to Buy at Zacks Investment Research

ARGENX SE-ADR (NASDAQ:ARGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage currently has a $26.00 price target on the stock. Zacks Investment Research‘s price target suggests a potential upside of 13.44% from the stock’s previous close.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

Separately, Cowen and Company reiterated a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th.

Shares of ARGENX SE-ADR (ARGX) traded down 2.47% during midday trading on Tuesday, reaching $22.92. 19,411 shares of the company’s stock traded hands. The stock’s market cap is $615.88 million. The stock has a 50 day moving average of $23.26 and a 200-day moving average of $21.52. ARGENX SE-ADR has a 12 month low of $17.33 and a 12 month high of $27.25.

ILLEGAL ACTIVITY WARNING: “ARGENX SE-ADR (ARGX) Rating Increased to Buy at Zacks Investment Research” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/10/31/argenx-se-adr-argx-rating-increased-to-buy-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nicholas Investment Partners LP acquired a new position in shares of ARGENX SE-ADR during the second quarter valued at about $236,000. DAFNA Capital Management LLC acquired a new position in shares of ARGENX SE-ADR during the second quarter valued at about $848,000. Tekla Capital Management LLC acquired a new position in shares of ARGENX SE-ADR during the second quarter valued at about $1,591,000. AWM Investment Company Inc. acquired a new position in shares of ARGENX SE-ADR during the second quarter valued at about $2,121,000. Finally, Jennison Associates LLC acquired a new position in shares of ARGENX SE-ADR during the second quarter valued at about $2,657,000. Hedge funds and other institutional investors own 22.74% of the company’s stock.

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

What are top analysts saying about ARGENX SE-ADR? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ARGENX SE-ADR and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit